| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC11707 | MDVN-1003 | A first-in-class, selective, orally bioavailable, dual inhibitor of BTK and PI3Kδ kinases with IC50 of 32.3 nM and 16.9 nM, respectively. |
|
| DC11804 | IQS-019 | A novel, potent inhibitor of most upstream tyrosine kinases in BCR signaling pathway, inhibits BCR kinases Lyn, Syk and Btk with IC50 of 0.15 uM, 1.6 uM and 2.1 uM, respectively. |
|
| DC11805 | IQS-019 mesylate | A novel, potent inhibitor of most upstream tyrosine kinases in BCR signaling pathway, inhibits BCR kinases Lyn, Syk and Btk with IC50 of 0.15 uM, 1.6 uM and 2.1 uM, respectively. |
|
| DC9660 | Acalabrutinib(ACP196) Featured | Acalabrutinib (ACP-196) is a second-generation, selective, irreversible inhibitor of BTK. |
|
| DC10975 | ARQ-531 Featured | ARQ-531 is a potent, reversible, orally available inhibitor of both wild type and C481S-mutant BTK kinase with IC50 of 0.85 and 0.39 nM, |
|
| DC5014 | AVL-292 Featured | AVL-292 is a covalent, highly selective, orally active small molecule inhibitor of Btk currently being evaluated in a Phase 1b clinical trial in relapsed. |
|
| DC10335 | BGB-3111 | BGB-3111 is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor. |
|
| DC11819 | BMS-986142 Featured | BMS-986142 is a potent, selective, and reversible BTK (Bruton’s tyrosine kinase) inhibitor (BTK IC₅₀ = 0.5nM; human WB IC₅₀ = 90 nM). |
|
| DC12030 | BMS-986195 Featured | BMS-986195 is a potent, covalent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK). |
|
| DC7380 | CGI-1746 Featured | CGI1746 is a small-molecule Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation. |
|
| DC10380 | Evobrutinib Featured | Evobrutinib is an inhibitor of Bruton's tyrosin kinase (Btk) inhibitor extracted from patent US20140162983 example 0174. |
|
| DC7937 | LFM-A13 Featured | FM-A13 is a selective inhibitor of Bruton’s tyrosine kinase (BTK) – IC₅₀’s = 2.5 µM (recombinant BTK) and 17.2 µM (human BTK). |
|
| DC11776 | G-744 | G-744 is a highly potent, selective inhibitor of BTK with biochemical Ki of 1.28 nM. |
|
| DC9942 | GDC-0853(RG7845) Featured | GDC-0853 is orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. |
|
| DC10043 | ONO4059 hydrochloride Featured | ONO-4059 is a highly selective, orally bioavailable BTK inhibitor with a potency (IC50) of 2.2 nM. |
|
| DC8358 | ONO-4059(Tirabrutinib) Featured | ONO-4059 is a novel Small Molecule Dual Inhibitor Of Bruton’s Tyrosine Kinase (Btk) and Tec Kinase. |
|
| DC10757 | PCI-29732 Featured | PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay. |
|
| DC1106 | PCI-32765 (Ibrutinib) Featured | PCI-32765 (Ibrutinib) is a potent and highly selective Btk inhibitor with IC50 of 0.5 nM. |
|
| DC11914 | Poseltinib Featured | Poseltinib (HM-71224, LY-3337641) is a potent and selective, covalent inhibitor of Btk with IC50 of 1.95 nM. |
|
| DC5146 | RN486 Featured | RN-486 is a Bruton's tyrosine kinase (Btk) inhibitor. |
|
| DC10044 | ONO4059 analog Featured | The product is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor with an IC50 in the sub-nM range. |
|
| DC11471 | BGB-3111(Zanubrutinib) Featured | Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor. |
|
| DC28073 | CNX-500 Featured | CNX-500 is a probe consisting of a covalent Btk inhibitor (CC-292) chemically linked to biotin. CNX-500 retains inhibitory activity against Btk (IC50 of 0.5 nM) and the ability to form a covalent bond with Btk. CNX-500 has low inhibitory effects on kinase epidermal growth factor receptor, and upstream Src-family kinases including Syk and Lyn. |
|
| DC31047 | ABBV-105 | ABBV-105 (ABBV105) is a potent, selective, irreversible, covalent inhibitor of BTK with IC50 of 0.18 uM. |
|
| DC31049 | CB-988 | CB-988 is a potent, highly selective, non-covalent Btk inhibitor targering ibrutinib-resistant Btk C481S mutant (IC50=0.6 nM). |
|
| DC31063 | PCI-32765 racemate | A potent a+M7692nd highly selective Btk inhibitor with IC50 of 0.5 nM. |
|
| DC39103 | Remibrutinib (LOU064) Featured | Remibrutinib (LOU064) is a potent, highly selective covalent inhibitor of bruton tyrosine kinase (BTK) with IC50 of 1.3 nM, 2.5 nM and 18 nM for BTK, FcγR-induced IL8 and anti-IgM/IL4-induced CD69, respectively. Remibrutinib (LOU064) exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for the treatment of autoimmune diseases. |
|
| DC40447 | N-piperidine Ibrutinib hydrochloride | N-piperidine Ibrutinib hydrochloride (Compound 1) is a reversible Ibrutinib derivative. N-piperidine Ibrutinib hydrochloride is a potent BTK inhibitor with IC50s of 51.0 and 30.7 nM for WT BTK and C481S BTK, respectively. N-piperidine Ibrutinib hydrochloride can be used as a BTK ligand in the synthesis of a series of PROTACs, such as SJF620. SJF620 is a potent PROTAC BTK degrader with a DC50 of 7.9 nM. |
|
| DC41102 | Acalabrutinib D4 | Acalabrutinib D4 (ACP-196 D4) is a deuterium labeled Acalabrutinib. Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. |
|
| DC41149 | Ibrutinib deacryloylpiperidine | Ibrutinib deacryloylpiperidine (IBT4A) is an impurity of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM. |
|
